BLAINJECTIONINJECTABLEPriority Review
Approved
Mar 2011
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
5/8 — Partial
Priority Review
YERVOY (ipilimumab) by Bristol Myers Squibb is ctla-4-directed antibody interactions [moa]. Approved for ctla-4-directed blocking antibody [epc]. First approved in 2011.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YERVOY (ipilimumab) is a monoclonal antibody that blocks CTLA-4, a checkpoint inhibitor that unleashes anti-tumor immune responses. It is approved for melanoma and other solid tumors where it enhances T-cell activation against cancer cells. The drug pioneered checkpoint inhibitor immunotherapy and fundamentally changed oncology treatment paradigms.
$13MPart D
LOE ApproachingLOE approaching signals team consolidation and transition focus toward combination therapies and new indications rather than monotherapy growth.
Mechanism of Action
CTLA-4-directed Antibody Interactions
Pharmacologic Class:
CTLA-4-directed Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
Started Dec 2026
550 enrolled
Melanoma (Skin Cancer)Advanced MelanomaMetastatic Melanoma+1 more
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Started Jul 2026
26 enrolled
Non-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Recurrent
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Started Apr 2026
120 enrolled
Advanced Renal Cell Carcinoma (aRCC)Metastatic Renal Cell Carcinoma ( mRCC)Clear Cell Renal Cell Carcinoma (ccRCC)
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Started Mar 2026
105 enrolled
Hepato Cellular Carcinoma (HCC)
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Started Mar 2026
198 enrolled
Hepatocellular Carcinoma (HCC)
Worked on YERVOY at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.